Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1624 1629 1656
This examiner grants 56% of resolved cases
Allen Chao works in Tech Center 1600 and Art Unit 1622. He has 9 resolved cases with an allowance rate of 55.6 percent. The median days to allowance is 1104.
The interview lift is 0.0 percent, based on the 9 cases he has handled. This suggests that interviews have not changed the outcome in this limited data set. Practitioners should focus on written arguments to navigate the 55.6 percent allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18562666 | METHOD FOR CRYSTALLIZATION OF AROMATIC AMINO ACIDS, ENABLING SUSTAINABLE CYCLE OF AMMONIA | Final Rejection | CJ CheilJedang Corporation |
| 18449793 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND ABEMACICLIB OR RIBOCICLIB | Non-Final OA | Genentech, Inc. |
| 18293683 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | Non-Final OA | The Johns Hopkins University |
| 18709395 | Prodrugs of Neurosteroid Analogs and Uses Thereof | Non-Final OA | Emory University |
| 18685544 | PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | Non-Final OA | BASF SE |
| 18606577 | ANTIMICROBIAL COMPOSITIONS WITH ENHANCED EFFICACY | Final Rejection | ECOLAB USA INC. |
| 18615156 | THERAPEUTIC LIQUID COMPOSITIONS | Final Rejection | Kenvue Brands LLC |
| 18602132 | METHODS FOR TREATING CYTOKINE STORM ASSOCIATED WITH ACINETOBACTER BAUMANNII INFECTIONS | Final Rejection | City University of Hong Kong |
| 18602519 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Non-Final OA | SANOFI |
| 18685551 | LOU064 FOR TREATING MULTIPLE SCLEROSIS | Final Rejection | NOVARTIS AG |
| 18844280 | INHIBITORS OF FLI1 AND ERG | Non-Final OA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION |
| 18219447 | PROCESS FOR PREPARING PHOSPHONATE ESTERS | Final Rejection | ENTEGRIS, INC. |
| 18696946 | Heterocyclic Compounds and Methods of Use | Non-Final OA | AMGEN INC. |
| 18293768 | PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE | Non-Final OA | Firmenich SA |
| 18293766 | PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE | Non-Final OA | Firmenich SA |
| 18602434 | Bicyclic Ureas As Kinase Inhibitors | Non-Final OA | Incyte Corporation |
| 18584553 | Heterocyclic Compounds As Kinase Inhibitors | Non-Final OA | Incyte Corporation |
| 18512625 | Heteroaryl Fluoroalkenes As DGK Inhibitors | Non-Final OA | Incyte Corporation |
| 18512514 | Heteroaryl Fluoroalkenes As DGK Inhibitors | Non-Final OA | Incyte Corporation |
| 18844216 | PROCESSES FOR SYNTHESIS OF WITHANOLIDES AND WITHAFERINS AND ANALOGS THEREOF | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18729657 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS | Non-Final OA | KSQ Therapeutics, Inc. |
| 18263434 | ORAL PREPARATION CONTAINING JAK INHIBITOR OR SALT THEREOF OR CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Final Rejection | ZHUHAI UNITED LABORATORIES CO., LTD. |
| 18283487 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Final Rejection | Vicore Pharma AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy